Migraine patchmaker NuPathe chooses buyer Teva over Endo; Alnylam enters PhI with hemophilia RNAi drug;

> NuPathe, the maker of the Zecuity transdermal patch for migraine treatment, decided not to accept Endo Health Solutions' ($ENDP) offer of about $105 million and opted instead for Teva Pharmaceutical Industries' ($TEVA) offer of about $114 milliion. More

> Alnylam ($ALNY) entered the clinic with its RNAi candidate ALN-AT3. The Phase I trial will focus on the treatment of hemophilia and rare bleeding disorders. Release

> New Jersey-based Alitair Pharmaceuticals won a U.S. patent for its ion exchange resin drug delivery technology. Release

Suggested Articles

J&J figures its partner Genmab owes a share of Darzalex Faspro royalties to Halozyme for its subcutaneous delivery tech. Genmab doesn't agree.

Bexson Biomedical and Stevanato Group teamed up to develop a ketamine pump that may help patients better manage pain at home.

Australia's University of New South Wales and Uka Tarsadia University in India will join forces to explore contact lenses for ocular drug delivery.